Evidence map›Paper›PMID 41383852›Full record

ArticleFrontiers in cellular and infection microbiology2025

Relationship between LILRB2 and APE1 levels and pathological characteristics in colorectal cancer patients and their predictive value for prognosis.

Ji Li, Xiaofang Tang, MianYong Wu, JinMing Tu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ji Li *Gastroenterology Department, Longyou County People's Hospital, Longyou, Quzhou, Zhejiang, China.
Xiaofang Tang *Gastroenterology Department, Tongxiang First People's Hospital, Tongxiang, Jiaxing, Zhejiang, China.
MianYong WuGastroenterology Department, Longyou County People's Hospital, Longyou, Quzhou, Zhejiang, China.
JinMing TuGastroenterology Department, Longyou County People's Hospital, Longyou, Quzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to investigate the relationship between the expression levels of Leukocyte Immunoglobulin-Like Receptor Subfamily B2 (LILRB2) and Apurinic/Apyrimidinic Endonuclease 1 (APE1) and the pathological characteristics in colorectal cancer (CRC) patients, as well as their predictive value for prognosis. Methods: Serum levels of LILRB2 and APE1 were analyzed in CRC patients with varying pathological characteristics. The associations between LILRB2 and APE1 serum levels and patient prognosis was evaluated, and factors influencing prognosis were identified. Results: Patients with high LILRB2 expression exhibited a significantly lower survival rate than those with low expression, and the same trend was observed for APE1 expression (both Conclusion: Abnormal expression levels of LILRB2 and APE1 are associated with age, tumor diameter, TNM stage, and LNM in CRC patients. Elevated expression of these markers predicts a poorer prognosis.

Indexed as

Colorectal NeoplasmsDNA-(Apurinic or Apyrimidinic Site) LyaseMembrane GlycoproteinsReceptors, ImmunologicAdultAgedBiomarkers, TumorFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPrognosisAPEX1 protein, humanBiomarkers, TumorDNA-(Apurinic or Apyrimidinic Site) LyaseLILRB2 protein, humanMembrane GlycoproteinsReceptors, ImmunologicApurinic/apyrimidinic endonuclease 1 (APE1)colorectal cancerCox regression analysisLeukocyte Immunoglobulin-Like Receptor Subfamily B2 (LILRB2)pathological characteristicsprognosis

Identifiers

PMID41383852
PMCPMC12689926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.